The significant association of Taq1A genotypes in DRD2/ANKK1 with smoking cessation in a large-scale meta-analysis of Caucasian populations

Translational Psychiatry

Volumn 5, Issue , 2015, Pages

  Ma, Y ^a   Wang, M ^a   Yuan, W ^a   Su, K ^a   Li, M D ^a,b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANKK1 PROTEIN; DRD2 PROTEIN; TAQ POLYMERASE; TAQ1A POLYMERASE; UNCLASSIFIED DRUG; ANKK1 PROTEIN, HUMAN; DOPAMINE 2 RECEPTOR; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CAUCASIAN; CROSS-SECTIONAL STUDY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LONGITUDINAL STUDY; META ANALYSIS; NEOPLASM; PUBLISHING; SMOKING; SMOKING CESSATION; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; TOBACCO USE DISORDER;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, DOPAMINE D2; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 84948739244     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.176     Document Type: Article

References (76)

1. WHO. WHO Tobacco Fact sheet N°339. http://www.who.int/mediacentre/fact sheets/fs339/en/, 2014.
2. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003; 98: 23-31.
3. True WR, Heath AC, Scherrer JF, Waterman B, Goldberg J, Lin N et al. Genetic and environmental contributions to smoking. Addiction 1997; 92: 1277-1287.
4. Sullivan PF, Kendler KS. The genetic epidemiology of smoking. Nicotine Tob Res 1999; 1: S51-S57; discussion S69-70.
5. Xian H, Scherrer JF, Madden PA, Lyons MJ, Tsuang M, True WR et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob Res 2003; 5: 245-254.
6. Hardie TL, Moss HB, Lynch KG. Genetic correlations between smoking initiation and smoking behaviors in a twin sample. Addict Behav 2006; 31: 2030-2037.
7. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictivecompulsive behaviour. Pharmacogenetics 1995; 5: 121-141.
8. Li MD. The genetics of nicotine dependence. Curr Psychiatry Rep 2006; 8: 158-164.
9. Ma Y, Yuan W, Jiang X, Cui WY, Li MD. Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions. Mol Neurobiol 2014; 51: 281-299.
10. Gelernter J, Yu Y, Weiss R, Brady K, Panhuysen C, Yang BZ et al. Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Hum Mol Genet 2006; 15: 3498-3507.
11. Huang W, Payne TJ, Ma JZ, Beuten J, Dupont RT, Inohara N et al. Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample. Neuropsychopharmacology 2009; 34: 319-330.
12. Wei J, Chu C, Wang Y, Yang Y, Wang Q, Li T et al. Association study of 45 candidate genes in nicotine dependence in Han Chinese. Addict Behav 2012; 37: 622-626.
13. Ducci F, Kaakinen M, Pouta A, Hartikainen AL, Veijola J, Isohanni M et al. TTC12-ANKK1-DRD2 and CHRNA5-CHRNA3-CHRNB4 influence different pathways leading to smoking behavior from adolescence to mid-adulthood. Biol Psychiatry 2011; 69: 650-660.
14. De Ruyck K, Nackaerts K, Beels L, Werbrouck J, De Volder A, Meysman M et al. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. Pharmacogenomics 2010; 11: 1053-1063.
15. Morton LM, Wang SS, Bergen AW, Chatterjee N, Kvale P, Welch R et al. DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Pharmacogenet Genomics 2006; 16: 901-910.
16. Voisey J, Swagell CD, Hughes IP, van Daal A, Noble EP, Lawford BR et al. A DRD2 and ANKK1 haplotype is associated with nicotine dependence. Psychiatry Res 2012; 196: 285-289.
17. Noble EP, Jeor ST, Ritchie T, Syndulko K, Jeor SC, Fitch RJ et al. D2 dopamine receptor gene and cigarette smoking: a reward gene Med Hypotheses 1994; 42: 257-260.
18. Johnstone EC, Yudkin P, Griffiths SE, Fuller A, Murphy M, Walton R. The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK population. Addict Biol 2004; 9: 221-226.
19. Wernicke C, Reese J, Kraschewski A, Winterer G, Rommelspacher H, Gallinat J. Distinct haplogenotypes of the dopamine D2 receptor gene are associated with non-smoking behaviour and daily cigarette consumption. Pharmacopsychiatry 2009; 42: 41-50.
20. Bierut LJ, Rice JP, Edenberg HJ, Goate A, Foroud T, Cloninger CR et al. Familybased study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet 2000; 90: 299-302.
21. Wu X, Hudmon KS, Detry MA, Chamberlain RM, Spitz MR. D2 dopamine receptor gene polymorphisms among African-Americans and Mexican-Americans: a lung cancer case-control study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1021-1026.
22. Ohmoto M, Takahashi T, Kubota Y, Kobayashi S, Mitsumoto Y. Genetic influence of dopamine receptor, dopamine transporter, and nicotine metabolism on smoking cessation and nicotine dependence in a Japanese population. BMC Genet 2014; 15: 151.
23. Gordiev M, Engstrom PF, Khasanov R, Moroshek A, Sitdikov R, Dgavoronkov V et al. Genetic analysis of polymorphisms in dopamine receptor and transporter genes for association with smoking among cancer patients. Eur Addict Res 2013; 19: 105-111.
24. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996; 6: 73-79.
25. Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, Hu S et al. A genetic association for cigarette smoking behavior. Health Psychol 1999; 18: 7-13.
26. Singleton AB, Thomson JH, Morris CM, Court JA, Lloyd S, Cholerton S. Lack of association between the dopamine D2 receptor gene allele DRD2∗A1 and cigarette smoking in a United Kingdom population. Pharmacogenetics 1998; 8: 125-128.
27. Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H, Chamberlain RM et al. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 1998; 90: 358-363.
28. Munafo M, Clark T, Johnstone E, Murphy M, Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 2004; 6: 583-597.
29. Munafo MR, Timpson NJ, David SP, Ebrahim S, Lawlor DA. Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine Tob Res 2009; 11: 64-76.
30. Li MD, Ma JZ, Beuten J. Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet 2004; 66: 382-392.
31. Ohmoto M, Sakaishi K, Hama A, Morita A, Nomura M, Mitsumoto Y. Association between dopamine receptor 2 TaqIA polymorphisms and smoking behavior with an influence of ethnicity: a systematic review and meta-analysis update. Nicotine Tob Res 2013; 15: 633-642.
32. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991; 48: 648-654.
33. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK et al. D2 dopamine receptor gene (DRD2) Taq1A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7: 479-484.
34. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3: 256-260.
35. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4: 290-296.
36. Yudkin P, Munafo M, Hey K, Roberts S, Welch S, Johnstone E et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 2004; 328: 989-990.
37. Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004; 14: 83-90.
38. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22: 541-548.
39. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 2007; 9: 821-833.
40. Berlin I, Covey LS, Jiang H, Hamer D. Lack of effect of D2 dopamine receptor TaqI A polymorphism on smoking cessation. Nicotine Tob Res 2005; 7: 725-728.
41. Munafo MR, Johnstone EC, Murphy MF, Aveyard P. Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine Tob Res 2009; 11: 404-407.
42. Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002; 12: 627-634.
43. Swan GE, Jack LM, Valdes AM, Ring HZ, Ton CC, Curry SJ et al. Joint effect ofdopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol 2007; 26: 361-368.
44. Choi HD, Shin WG. Lack of association between DRD2 Taq1A gene polymorphism and smoking cessation therapy: a meta-analysis. Int J Clin Pharmacol Ther 2015; 53: 415-421.
45. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
46. Yoshida K, Hamajima N, Kozaki K, Saito H, Maeno K, Sugiura T et al. Association between the dopamine D2 receptor A2/A2 genotype and smoking behavior in the Japanese. Cancer Epidemiol Biomarkers Prev 2001; 10: 403-405.
47. Hamajima N, Ito H, Matsuo K, Saito T, Tajima K, Ando M et al. Association between smoking habits and dopamine receptor D2 taqI A A2 allele in Japanese males: a confirmatory study. J Epidemiol 2002; 12: 297-304.
48. Styn MA, Nukui T, Romkes M, Perkins K, Land SR, Weissfeld JL. The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 254-261.
49. Han DH, Joe KH, Na C, Lee YS. Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers. Psychiatr Genet 2008; 18: 11-16.
50. Tashkin DP, Rabinoff M, Noble EP, Ritchie TL, Simmons MS, Connett J. Association of dopamine-related gene alleles, smoking behavior and decline in FEV1 in subjects with COPD: findings from the lung health study. COPD 2012; 9: 620-628.
51. Ton TG, Rossing MA, Bowen DJ, Srinouanprachan S, Wicklund K, Farin FM. Genetic polymorphisms in dopamine-related genes and smoking cessation in women: a prospective cohort study. Behav Brain Funct 2007; 3: 22.
52. Stapleton JA, Sutherland G, O'Gara C, Spirling LI, Ball D. Association between DRD2/ANKK1 Taq1A genotypes, depression and smoking cessation with nicotine replacement therapy. Pharmacogenet Genomics 2011; 21: 447-453.
53. Cinciripini P, Wetter D, Tomlinson G, Tsoh J, De Moor C, Cinciripini L et al. The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 2004; 6: 229-239.
54. Breitling LP, Twardella D, Hoffmann MM, Witt SH, Treutlein J, Brenner H. Prospective association of dopamine-related polymorphisms with smoking cessation in general care. Pharmacogenomics 2010; 11: 527-536.
55. Wilcox CS, Noble EP, Oskooilar N. ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data. J Investig Med 2011; 59: 1280-1283.
56. Stapleton JA, Sutherland G, O'Gara C. Association between dopamine transporter genotypes and smoking cessation: a meta-analysis. Addict Biol 2007; 12: 221-226.
57. Ma YL, Yuan WJ, Cui WY, Li MD. Meta-analysis reveals significant association of 3'-UTR VNTR in SLC6A3 with smoking cessation in Caucasian populations. Pharmacogenomics J 2015. doi: 10.1038/tpj.2015.44.
58. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
59. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
60. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA 2007; 104: 20552-20557.
61. Moyer RA, Wang D, Papp AC, Smith RM, Duque L, Mash DC et al. Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. Neuropsychopharmacology 2011; 36: 753-762.
62. Al-Eitan LN, Jaradat SA, Hulse GK, Tay GK. Custom genotyping for substance addiction susceptibility genes in Jordanians of Arab descent. BMC Res Notes 2012; 5: 497.
63. Sullivan D, Pinsonneault JK, Papp AC, Zhu H, Lemeshow S, Mash DC et al. Dopamine transporter DAT and receptor DRD2 variants affect risk of lethal cocaine abuse: a gene-gene-environment interaction. Transl Psychiatry 2013; 3: e222.
64. Sasabe T, Furukawa A, Matsusita S, Higuchi S, Ishiura S. Association analysis of the dopamine receptor D2 (DRD2) SNP rs1076560 in alcoholic patients. Neurosci Lett 2007; 412: 139-142.
65. Doehring A, Hentig N, Graff J, Salamat S, Schmidt M, Geisslinger G et al. Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics 2009; 19: 407-414.
66. Clarke TK, Weiss AR, Ferarro TN, Kampman KM, Dackis CA, Pettinati HM et al. The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction. Ann Hum Genet 2013; 78: 33-39.
67. Zheng C, Shen Y, Xu Q. Rs1076560, a functional variant of the dopamine D2 receptor gene, confers risk of schizophrenia in Han Chinese. Neurosci Lett 2012; 518: 41-44.
68. Chien YL, Hwu HG, Fann CS, Chang CC, Tsuang MT, Liu CM. DRD2 haplotype associated with negative symptoms and sustained attention deficits in Han Chinese with schizophrenia in Taiwan. J Hum Genet 2013; 58: 229-232.
69. Glatt SJ, Faraone SV, Lasky-Su JA, Kanazawa T, Hwu HG, Tsuang MT. Family-based association testing strongly implicates DRD2 as a risk gene for schizophrenia in Han Chinese from Taiwan. Mol Psychiatry 2009; 14: 885-893.
70. Blasi G, Lo Bianco L, Taurisano P, Gelao B, Romano R, Fazio L et al. Functional variation of the dopamine D2 receptor gene is associated with emotional control as well as brain activity and connectivity during emotion processing in humans. J Neurosci 2009; 29: 14812-14819.
71. Blasi G, Napolitano F, Ursini G, Taurisano P, Romano R, Caforio G et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci USA 2011; 108: 1158-1163.
72. Hoenicka J, Quinones-Lombrana A, Espana-Serrano L, Alvira-Botero X, Kremer L, Perez-Gonzalez R et al. The ANKK1 gene associated with addictions is expressed in astroglial cells and upregulated by apomorphine. Biol Psychiatry 2010; 67: 3-11.
73. Garrido E, Palomo T, Ponce G, Garcia-Consuegra I, Jimenez-Arriero MA, Hoenicka J. The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine. Neurotox Res 2011; 20: 32-39.
74. Munafo MR, Matheson IJ, Flint J. Association of the DRD2 gene Taq1A polymorphism and alcoholism: a meta-analysis of case-control studies and evidence of publication bias. Mol Psychiatry 2007; 12: 454-461.
75. Tobacco Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 2010; 42: 441-447.
76. Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, Lockshin B et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 1999; 18: 14-20.